What Clinicians Want to Know About the Management of Triple-Negative Breast Cancer

What Clinicians Want to Know About the Management of Triple-Negative Breast Cancer
Proceedings from a webinar on June 20, 2024, moderated by Dr Neil Love. Featuring perspectives from Dr Kevin Kalinsky and Dr Heather McArthur. Published July 10, 2024.
Topics:
• Introduction (0:00)
• Case: A woman in her mid 80s with a 2.7-cm residual tumor after neoadjuvant pembrolizumab/chemotherapy for localized triple-negative breast cancer (TNBC) - Ranju Gupta, MD (3:31)
• Question and Comments: Approach to neoadjuvant therapy and defining residual disease; PD-L1 status and efficacy of pembrolizumab in the localized and metastatic settings - Kapisthalam (KS) Kumar, MD (8:04)
• Case: A woman in her mid 60s with node-positive TNBC and a single lung metastasis who receives neoadjuvant therapy based on the KEYNOTE-522 trial - Dr Kumar (17:18)
• Case: A woman in her early 70s with localized TNBC and residual disease after poorly tolerated neoadjuvant pembrolizumab/chemotherapy and lumpectomy - Dr Kumar (23:29)
• Case: A woman in her late 60s with widely metastatic ER-negative, HER2-low disease after multiple lines of treatment - CDH1 and ERBB2-V697L mutations, microsatellite stable, tumor mutational burden 3 mut/Mb - Dr Gupta (29:13)
• Question and Comments: Adjuvant therapy selection for patients with localized TNBC with a BRCA mutation and residual disease; risk of acute myeloid leukemia/myelodysplastic syndromes associated with PARP inhibitor therapy - Dr Kumar (40:52)
• Case: A woman in her early 70s who develops recurrent metastatic ER-negative, HER2-low breast cancer after nab paclitaxel/atezolizumab and receives sacituzumab govitecan - Dr Gupta (46:49)
The entire program, slides, CME information, and, select publications:
www.researchto...